The company said it filed a definitive proxy statement for the 2024 Annual Meeting of Shareholders, to be held on December 10, 2024, and that this filing supplements the information in that proxy statement. The proxy statement was filed on October 29, 2024.

1. 01

   The company said it filed a definitive proxy statement for the 2024 Annual Meeting of Shareholders, to be held on December 10, 2024, and that this filing supplements the information in that proxy statement. The proxy statement was filed on October 29, 2024.

2. 02

   The company said that on November 10, 2024, it granted additional equity awards for a total of 1,467,999 shares under its 2021 Equity Incentive Plan. It said that immediately after these grants, 11,505,724 shares remained available for grant under the 2021 Plan.

3. 03

   The company said it expects to grant restricted stock units for approximately 23,397 shares and performance stock units for up to approximately 338,607 shares under the 2021 Plan before the Annual Meeting. It said these grants are subject to approval by its board of directors or an appropriate committee thereof.

4. 04

   The company said that as of November 10, 2024, there were 4,181,136 outstanding stock options (including PSOs), with a weighted-average exercise price of $65.30 per share and a weighted-average remaining duration of 0.97 years. It also said there were 14,636,462 restricted stock units (including PSUs) outstanding.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.